New efficacy and safety data will be provided by the ongoing phase III PYRAMID-1 trial comparing pyrotinib with docetaxel in patients with advanced NSCLC harbouring a HER2 exon 20 mutation who have been previously treated with platinum-based chemotherapy (NCT04447118). Here, ERBB2 is linked to non-small cell lung carcinoma.